Hong Kong Stock Movement | HENLIUS (02696) Surges Nearly 9% as IND Applications for Three Innovative Solid Tumor Drugs Are Accepted Concurrently

Stock News01-05

HENLIUS (02696) is currently up nearly 9%. As of the time of writing, the stock has risen 8.62% to HK$63.65, with a turnover of HK$29.04 million. On December 30, HENLIUS announced that the Investigational New Drug (IND) applications for three of its promising innovative molecules have been accepted by the National Medical Products Administration (NMPA). These include the DLL3xDLL3xCD3xCD28 tetra-specific T-cell engager HLX3901, developed based on its proprietary TCE platform; the potential best-in-class (BIC) novel oral small-molecule KAT6A/B inhibitor HLX97; and the potential first-in-class (FIC) B7H3-sialidase fusion protein HLX316. All three products are intended for the treatment of solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment